Navigation Links
Antibody Technologies and Attrition Rates - An Industry Analysis 2013

DUBLIN, Ireland, April 16, 2013 /PRNewswire/ --

Research and Markets announces the addition of "Antibody Technologies and Attrition Rates - an industry analysis 2013" to its catalogue.

     (Logo: )

The report Antibody Technologies and Attrition Rates - an industry analysis 2013 is based on the identification of the antibody generation technologies of 504 naked antibodies in clinical or market stages. Information was retrieved from scientific and corporate publications as well as from patent and legal literature. The report provides descriptive statistics of the 504 naked antibodies and their status during the study period of January 1, 2013 to February 28, 2013. The antibodies are categorized as active during the study period or discontinued during or before the study period. Attrition rates were calculated across a number of variables.

Descriptive statistics of the 504 naked antibodies include the following variables:

- Unique antibody identifiers (drug codes; generic name; brand name)
- Antibody format (full length, Fab, scFv, VH/VL, nanobody, bispecific, cocktail/polyclonal)
- In vitro antibody generation technologies (display technologies from CAT, Dyax, Morphosys, BioInvent, Domantis, Genentech, others)
- In vivo antibody generation technologies (chimeric, primatized, nanobodies, deimmunized, human engineered, humaneered, humanized, XenoMouse, HuMab mouse, KM mouse, VelocImmune mouse, human B-cell derived)
- Animal species of parental wild-type antibody (mouse, rat, rabbit, hamster, cynomolgus monkey, camelid)
- Antibody status (active/discontinued)
- Year of failure
- Reason for failure (efficacy, pharmacokinetics/ADME; safety; technical, business, next generation, inactivity)
- Target
- Immunoglobulin class and IgG isotype
- Highest phase
- Therapeutic area of lead indication
- Companies (developer, licensor/originator)

An Antibody Data Sheet was prepared for each unique antibody containing the retrieved information and the source of information in the form of a scientific reference or a hyperlink leading to the website from which the information was obtained.

The analysis essentially evaluated the question whether there are differences in clinical attrition rates between in vitro and in vivo antibody generation technologies as well as within the different in vitro and in antibody generation technologies. Attrition rate was defined as the percentage of failed antibodies of all active and inactive antibodies.

Reasons To Buy

Benefits from the data and the analysis include:

- Understand the historical and present state of the art use of antibody technologies;
- Learn the success rate of each antibody generation technology;
- Understand the reasons for failure of antibodies in clinical development;
- Appreciate the relative value of generic and of IP protected antibody technologies;
- Know which antibody technologies are using your competitors;
- Know the preferred antibody formats, IgG isotypes, development indications, parental wild-type animal species.
- Learn the influence of the target for the success rate of the selected antibody technology.

Key Topics Covered

Table of Contents

1 Executive Summary and Discussion

2 Introduction

3 Methodology

4 Results
4.1 Use of antibody technologies
4.2 Attrition rates
4.3 Reasons for failure
4.4 Antibody generation technologies and targets
4.5 Antibody technologies and antibody formats
4.6 Parental animal species of in vivo generated antibodies
4.7 Immunoglobulin class and isotype vs. antibody technology
4.8 Antibody technology and therapeutic areas
4.9 Attrition rates of antibodies in therapeutic areas
4.10 Benchmark analysis: big pharma and biotech antibody technology preferences and attrition rates

5 Tables
6 Addendum: Antibody Data Sheets

For more information please visit Research and Markets.

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contact Details

Research and Markets
Laura Wood , Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Sector: Pharmaceuticals

SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
2. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
3. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
4. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
5. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
6. Monoclonal Antibody Industry 2013 Global and China Market Analysis in New Research Report at
7. AnaptysBio Develops Novel Antibody Scaffold With Extreme Thermostability
8. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
9. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
10. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
11. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
Post Your Comments:
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
Breaking Medicine News(10 mins):